Although the role of radiation therapy is well established in this setting, the role of radical prostatectomy in treating men with de novo oligometastatic prostate cancer has not been well defined.

There is a high unmet need for effective neoadjuvant treatments for muscle-invasive bladder cancer for patients who cannot tolerate or refuse cisplatin chemotherapy.

Investigators identify causative pathogens and risk factors for post-cystectomy UTI and associations with survival.

Active surveillance may be an appropriate option for older patients and those with greater comorbidity burden and worse ...

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.

Discrepancies between clinical and pathologic staging of muscle-invasive bladder cancer (MIBC) are found in three-quarters of ...

A trial tested MRI and microultrasonography guided biopsy separately and in combination for the detection of clinically significant prostate cancer.

Credit: Thinkstock Investigators reported findings from a 2-sample Mendelian randomization analysis of large cohorts of participants in genome-wide association studies who were predominantly of ...

Higher weighted years with overweight/obesity linked to increased risk for overall, aggressive, fatal, and clear-cell renal cell carcinoma ...

(HealthDay News) — The U.S. Food and Drug Administration has launched the Chemical Contaminants Transparency Tool (CCT Tool), an online searchable database to evaluate potential health risks of ...